Supernus Pharmaceuticals (NASDAQ:SUPN) – Stock analysts at SunTrust Banks cut their FY2018 earnings per share estimates for Supernus Pharmaceuticals in a research report issued to clients and investors on Tuesday. SunTrust Banks analyst J. Boris now anticipates that the specialty pharmaceutical company will earn $1.84 per share for the year, down from their previous estimate of $1.96. SunTrust Banks also issued estimates for Supernus Pharmaceuticals’ FY2019 earnings at $2.52 EPS.
A number of other research firms have also issued reports on SUPN. BidaskClub upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Wednesday, January 10th. ValuEngine upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. B. Riley boosted their price objective on Supernus Pharmaceuticals from $50.00 to $54.00 and gave the company a “buy” rating in a research report on Thursday, December 28th. Finally, Berenberg Bank started coverage on Supernus Pharmaceuticals in a research report on Thursday, February 1st. They set a “buy” rating and a $66.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $51.36.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.18. Supernus Pharmaceuticals had a return on equity of 28.07% and a net margin of 18.95%. The business had revenue of $88.44 million during the quarter, compared to analyst estimates of $87.84 million.
In other Supernus Pharmaceuticals news, VP Victor Vaughn sold 55,000 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $40.11, for a total transaction of $2,206,050.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Gregory S. Patrick sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $43.56, for a total value of $2,178,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 165,750 shares of company stock worth $7,133,973 in the last ninety days. 6.70% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. Public Employees Retirement Association of Colorado bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth $188,000. Elkfork Partners LLC bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth $217,000. Sigma Planning Corp bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth $219,000. Parametrica Management Ltd bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth $247,000. Finally, Quantbot Technologies LP bought a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter worth $248,000. 96.21% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Brokers Issue Forecasts for Supernus Pharmaceuticals’ FY2018 Earnings (SUPN)” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3297824/brokers-issue-forecasts-for-supernus-pharmaceuticals-fy2018-earnings-supn.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.